[go: up one dir, main page]

MXPA04003534A - Derivados de lactam como antagonistas para receptores 11cby humanos. - Google Patents

Derivados de lactam como antagonistas para receptores 11cby humanos.

Info

Publication number
MXPA04003534A
MXPA04003534A MXPA04003534A MXPA04003534A MXPA04003534A MX PA04003534 A MXPA04003534 A MX PA04003534A MX PA04003534 A MXPA04003534 A MX PA04003534A MX PA04003534 A MXPA04003534 A MX PA04003534A MX PA04003534 A MXPA04003534 A MX PA04003534A
Authority
MX
Mexico
Prior art keywords
antagonists
receptors
lactam derivatives
11cby
human
Prior art date
Application number
MXPA04003534A
Other languages
English (en)
Inventor
Tadayyon Mohammad
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MXPA04003534A publication Critical patent/MXPA04003534A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/10—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D257/12—Six-membered rings having four nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invencion proporciona de esta manera los compuestos de la formula (I), una sal, o solvato de los mismos.
MXPA04003534A 2001-10-15 2002-10-15 Derivados de lactam como antagonistas para receptores 11cby humanos. MXPA04003534A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124627.1A GB0124627D0 (en) 2001-10-15 2001-10-15 Novel compounds
PCT/US2002/032740 WO2003033480A1 (en) 2001-10-15 2002-10-15 Lactam derivatives as antagonists for human 11cby receptors

Publications (1)

Publication Number Publication Date
MXPA04003534A true MXPA04003534A (es) 2004-07-22

Family

ID=9923785

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA04003534A MXPA04003534A (es) 2001-10-15 2002-10-15 Derivados de lactam como antagonistas para receptores 11cby humanos.
MXPA04003532A MXPA04003532A (es) 2001-10-15 2002-10-15 Pirimidinonas como receptor 1 de la hormona concentradora de melanina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA04003532A MXPA04003532A (es) 2001-10-15 2002-10-15 Pirimidinonas como receptor 1 de la hormona concentradora de melanina.

Country Status (21)

Country Link
EP (2) EP1436267B1 (es)
JP (2) JP2005510487A (es)
KR (2) KR20040045833A (es)
CN (2) CN1596247A (es)
AT (2) ATE356119T1 (es)
BR (2) BR0213040A (es)
CA (2) CA2463508A1 (es)
CO (2) CO5580779A2 (es)
CZ (2) CZ2004498A3 (es)
DE (2) DE60218721T2 (es)
ES (2) ES2279009T3 (es)
GB (1) GB0124627D0 (es)
HU (2) HUP0402335A3 (es)
IL (2) IL160872A0 (es)
MX (2) MXPA04003534A (es)
NO (2) NO20041504L (es)
NZ (1) NZ531911A (es)
PL (2) PL370587A1 (es)
RU (1) RU2004110053A (es)
WO (2) WO2003033476A1 (es)
ZA (2) ZA200402672B (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE446286T1 (de) 2001-11-26 2009-11-15 Schering Corp Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1618112A1 (en) * 2003-04-11 2006-01-25 SmithKline Beecham Corporation Heterocyclic mchr1 antagonists
CN100418965C (zh) * 2003-08-15 2008-09-17 万有制药株式会社 咪唑并吡啶衍生物
KR100747042B1 (ko) * 2003-08-19 2007-08-07 솔젠트 (주) 신물질６-메틸-３-펜에틸-３,４-디히드로-１ｈ-큐나졸린-２-티온,이의 제조방법 및 이를 유효성분으로 포함하는 미백 효능조성물
US20070078125A1 (en) * 2003-10-23 2007-04-05 Glaxo Group Limited Arylamine mch r1 antagonists
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
RU2358969C2 (ru) * 2004-02-13 2009-06-20 Баниу Фармасьютикал Ко., Лтд. Конденсированное 4-оксопиримидиновое производное
DE102004010893A1 (de) * 2004-03-06 2005-09-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue ß-Ketoamid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7605176B2 (en) 2004-03-06 2009-10-20 Boehringer Ingelheim International Gmbh β-ketoamide compounds with MCH antagonistic activity
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7902356B2 (en) 2004-12-17 2011-03-08 Eli Lilly And Company Thiazolopyridinone derivates as MCH receptor antagonists
CA2597541A1 (en) * 2005-02-14 2006-08-17 Banyu Pharmaceutical Co., Ltd. Crystal of 4(3h)-quinazolinone derivative
EP1876179B1 (en) * 2005-04-28 2015-03-25 Takeda Pharmaceutical Company Limited Thienopyrimidone compounds
WO2007011286A1 (en) * 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
WO2007027527A2 (en) * 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
US9040693B2 (en) * 2005-10-19 2015-05-26 Kissei Pharmaceutical Co., Ltd. Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
US7745447B2 (en) * 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
US8618115B2 (en) * 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
EP1966164B1 (en) 2005-12-21 2013-03-06 Janssen Pharmaceutica N.V. Novel substituted pyrazinone derivatives for use in mch-1 mediated diseases
US7553836B2 (en) * 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
CA2636879A1 (en) * 2006-02-15 2007-08-23 Sanofi-Aventis Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
CA2636605A1 (en) * 2006-02-15 2007-08-23 Lothar Schwink Novel azacycly-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments
RU2008136898A (ru) * 2006-02-15 2010-03-20 Санофи-Авентис (Fr) Азациклил-замещенные арилдигидроизохинолиноны, способ их получения и их применение в качестве лекарственных средств
JP2009526795A (ja) 2006-02-15 2009-07-23 サノフィ−アベンティス 新規なアミノアルコール置換アリールジヒドロイソキノリノン、それらの製造方法及び薬剤としてそれらの使用
WO2007142217A1 (ja) * 2006-06-07 2007-12-13 Banyu Pharmaceutical Co., Ltd. １－フェニルピリドン誘導体
WO2007146758A2 (en) 2006-06-08 2007-12-21 Eli Lilly And Company Novel mch receptor antagonists
WO2007146759A2 (en) 2006-06-08 2007-12-21 Eli Lilly And Company Novel mch receptor antagonists
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
WO2008020799A1 (en) * 2006-08-18 2008-02-21 Astrazeneca Ab Thienopyrimidin-4-one and thienopyridazin-7-one derivatives as mch rl antagonists
CA2664112C (en) 2006-12-05 2015-02-17 Janssen Pharmaceutica N.V. Novel substituted diaza-spiro-pyridinone derivatives for use in mch-1 mediated diseases
BRPI0721086A2 (pt) * 2006-12-14 2014-02-25 Lilly Co Eli Derivados de 5-[4-(azetidin-3-ilóxi)-fenil]-2-fenil-5h-tiazolo[5,4-c]piri din-4-ona e seu emprego como antago-nistas de receptor de mch
EP2121654A1 (en) 2007-01-10 2009-11-25 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles
EP2142554B1 (en) * 2007-04-25 2015-01-14 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
DE102007028925A1 (de) 2007-06-22 2008-12-24 Saltigo Gmbh Verfahren zur Herstellung von 2-Phenoxyacetalen und den daraus korrespondierenden 2-Phenoxycarbaldehyden
JP2010534248A (ja) 2007-07-21 2010-11-04 アルバニー モレキュラー リサーチ， インコーポレイテッド ５−ピリジノン置換インダゾール
WO2009072581A1 (ja) * 2007-12-05 2009-06-11 Aska Pharmaceutical Co., Ltd. ラクタム化合物又はその塩及びｐｐａｒ活性化剤
PE20091928A1 (es) * 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
CA2689707A1 (en) 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012036233A1 (ja) * 2010-09-17 2012-03-22 塩野義製薬株式会社 メラニン凝集ホルモン受容体アンタゴニスト活性を有する縮合へテロ環誘導体
BR112013021236B1 (pt) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp composto derivado de benzimidazol, e, composição
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120057A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101236188B1 (ko) * 2011-03-10 2013-02-22 한국화학연구원 신규한 피롤로피리디논 유도체 및 그의 ｍｃｈ 수용체-1 관련 질환에 대한 치료학적 용도
HUP1100241A3 (en) 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
NO3175985T3 (es) 2011-07-01 2018-04-28
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN106715424B (zh) 2014-06-05 2020-07-14 拜耳作物科学股份公司 作为农药的双环化合物
AU2016378723B2 (en) 2015-12-22 2021-09-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
ES2812817T3 (es) * 2016-08-12 2021-03-18 Bayer Cropscience Ag Método para la preparación de derivados de 4-sustituido-2,3-dihidro-1-benzofurano mediante la ciclación de sales de 2-(2-diazonio-6-sustituido fenil)-etanol
CN110121343B (zh) 2016-09-12 2023-11-03 整体健康 用作gpr120调节剂的双环化合物
CA3041033A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
MX2019014875A (es) 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
WO2019063708A1 (en) 2017-09-29 2019-04-04 Bayer Aktiengesellschaft SUBSTITUTED 3-PHENYLQUINAZOLIN-4 (3H) -ONES AND USES THEREOF
AR112840A1 (es) 2017-09-29 2019-12-18 Bayer Ag 3- fenilquinazolin-4(3h)-onas sustituidas y sus usos
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CN110563730B (zh) * 2019-07-29 2022-03-25 江苏理工学院 高纯度n10-三氟乙酰蝶酸的制备方法
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
CN113651800B (zh) * 2021-09-07 2022-08-19 山东铂源药业股份有限公司 一种甲磺酸奥希替尼的制备方法
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL137227B2 (en) * 1984-03-28 1986-05-31 Univ Lodzki Process for preparing novel n-/dialkylaminoalkoxyphenyl/-imides of tetrahydrophtalic acids
IL127296A (en) * 1996-12-31 2003-01-12 Reddy Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
AU7315700A (en) * 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist

Also Published As

Publication number Publication date
DE60218721T2 (de) 2007-11-15
CZ2004499A3 (cs) 2004-08-18
MXPA04003532A (es) 2004-07-22
CO5580778A2 (es) 2005-11-30
ES2279009T3 (es) 2007-08-16
DE60217147T2 (de) 2007-10-31
WO2003033476A1 (en) 2003-04-24
IL160872A0 (en) 2004-08-31
ES2283647T3 (es) 2007-11-01
ZA200402814B (en) 2005-04-13
EP1436267B1 (en) 2006-12-27
PL370587A1 (en) 2005-05-30
HUP0402346A2 (hu) 2005-02-28
KR20050043724A (ko) 2005-05-11
EP1442025A1 (en) 2004-08-04
KR20040045833A (ko) 2004-06-02
EP1442025B1 (en) 2007-03-07
CN1596247A (zh) 2005-03-16
PL370138A1 (en) 2005-05-16
CZ2004498A3 (cs) 2004-07-14
DE60217147D1 (de) 2007-02-08
CO5580779A2 (es) 2005-11-30
NZ531911A (en) 2004-11-26
RU2004110053A (ru) 2005-10-20
ATE349434T1 (de) 2007-01-15
CA2463508A1 (en) 2003-04-24
DE60218721D1 (en) 2007-04-19
CA2463509A1 (en) 2003-04-24
BR0213040A (pt) 2004-10-05
EP1436267A1 (en) 2004-07-14
ZA200402672B (en) 2005-04-05
ATE356119T1 (de) 2007-03-15
JP2005508966A (ja) 2005-04-07
BR0213242A (pt) 2004-09-28
JP2005510487A (ja) 2005-04-21
GB0124627D0 (en) 2001-12-05
NO20041504L (no) 2004-05-13
NO20041503L (no) 2004-05-13
WO2003033480A1 (en) 2003-04-24
IL161074A0 (en) 2004-08-31
HUP0402335A3 (en) 2006-02-28
CN1571774A (zh) 2005-01-26
HUP0402335A2 (hu) 2005-02-28

Similar Documents

Publication Publication Date Title
IL161074A0 (en) Lactam derivatives as antagonists for human 11cby receptors
IL185871A0 (en) N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor
IL157254A0 (en) N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
GB0130341D0 (en) Compounds
MXPA03001186A (es) Compuestos heterociclicos como ligandos del receptor acido gamma aminobutirico (gabaa).
MXPA05009985A (es) Ligandos de receptores de canabinoides.
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
MXPA05009508A (es) Derivados de nicotinamida 6-substituida como antagonistas de receptor opioide.
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
AU2003239389A1 (en) Opioid receptor antagonists
YU86603A (sh) Novi derivati piperidinkarboksamida, postupak za njihovo pripremanje i farmaceutske kompozicije koje ih sadrže
WO2003093247A3 (en) Antibacterial agents
TW200420561A (en) Antimicrobial 1-aryl dihydropyridone compounds
ZA200400824B (en) Pyridin-2-yl-methlyamine derivatives for treating opioid dependence.
ITVR20020030A1 (it) Miscela per polvere di saldatura, nonché procedimento per l'impiego di detta miscela.
AU2002345085A1 (en) Substituted $g(g)-lactone compounds serving as nmda antagonists
PL356412A1 (en) New compounds: derivatives of symmetrical 1,3,5- triazine